Regulation of MIR-143 using nucleic acid molecules
US11845935B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Mar 29, 2018 |
| Grant date | Dec 19, 2023 |
| Priority date | — |
| Expiry date | Mar 29, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/141
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Some embodiments of the invention include a nucleic acid molecule comprising natural nucleotides, non-natural nucleotides, an LNA which comprises one or more RNA core molecules, or an RNA molecule which comprises more than one RNA core molecule. Some embodiments of the invention include a nucleic acid molecule comprising an RNA molecule which comprises more than one RNA core molecule. Other embodiments of the invention include a nucleic acid molecule comprising a DNA molecule encoding the RNA molecule (e.g., vector or viral vector). Other embodiments include compositions or pharmaceutical compositions that comprise the nucleic acid molecule. Some embodiments of the invention comprise reducing miR-143 in a cell. Other embodiments of the invention include methods to deliver a protein across the BBB. Other embodiments include methods for treating disease (e.g., LSD, neuronopathic disease, neurodegenerative disease, Hurler syndrome, or MPS I). Additional embodiments of the invention are also discussed herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.